e-therapeutics plc

("e-therapeutics" or the "Company")

Notice of Annual General Meeting and Posting of Annual Report and Accounts

London, UK, 17 May 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces that its Annual Report and Accounts for the year ended 31 January 2022, which includes the notice of its 2022 Annual General Meeting ("AGM") have been posted to shareholders today and are available on the Company's website at:

https://www.etherapeutics.co.uk/application/files/1216/5167/3296/ETX_AR_2022.pdf

The AGM will be held at 12:30p.m. on 19 July 2022 at 4 Kingdom Street, Paddington, London, W2 6BD.

The right to attend and vote at the  AGM is determined by reference to the Company's register of members.  Only a member entered in the register of members as at close of business on 15 July 2022 (or, if the AGM is adjourned, in the register of members as at the close of business on the date which is two business days before the time of the adjourned  AGM) is entitled to attend and vote at the  AGM.

Shareholders who wish to register their votes on the resolutions to be put to the AGM should do so by completing and signing the proxy form that accompanies the notice of the AGM (or appoint a proxy electronically if their shares are held in CREST) in accordance with the instructions printed on the proxy form.

Please complete and return the form of proxy in accordance with the instructions printed thereon as soon as possible and, in any event, so that it is received by the Company's registrar, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, B62 8HD not later than 12:30p.m. on 15 July 2022.

If you do not have a proxy form and believe that you should have one, or if you have any additional queries on voting, please contact Neville Registrars Limited.

Enquiries:

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.